Compare Agilent Technologies Inc (A) vs MakeMyTrip Ltd (MMYT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs MakeMyTrip Ltd — how do they compare? Agilent Technologies Inc trades at $148.97 (market cap $42.22B), while MakeMyTrip Ltd trades at $60.29 (market cap $5.78B). The key difference: Agilent Technologies Inc is far larger — about 7.3× MakeMyTrip Ltd's market cap, and Agilent Technologies Inc pays a 0.68% dividend while MakeMyTrip Ltd pays none. Which is the better fit depends on your goals.
| A | MMYT | |
|---|---|---|
Market Cap | $42.22B | $5.78B |
Sector | Health | Technology |
52-Week High | $157.20 | $103.21 |
52-Week Low | $110.24 | $36.30 |
Enterprise Value | $43.77B | $6.44B |
Dividend Yield | 0.68% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agilent Technologies (A) trades at $148.72, up 1.88% with strong analyst support (77.5% buy ratings). The stock shows bullish technical momentum above key support levels, supported by consistent revenue around $6.9B and robust profitability with 19.55% net margins. Recent FDA approvals for diagnostic tests and the Biocare Medical acquisition enhance growth prospects in biopharma markets.
Outlook remains positive with a $154.90 consensus price target offering 4% upside, though high P/E of 30.02 poses valuation risk. Key catalysts include Q2 2026 earnings due August 26 and AI-driven lab expansion, while overbought RSI levels near 92 suggest near-term consolidation potential.
MakeMyTrip (MMYT) trades at $60.70, down 0.34% with a bullish technical signal supported by moving averages. The company reported strong Q1 2027 earnings with revenue growth in hotels and packages offsetting air-ticketing softness. Analysts maintain a 72.7% buy rating with a 34.1% upside target. Recent financials show $978M revenue and $95M net income for 2025, though 2026 projections indicate margin compression.
The stock presents growth potential driven by travel recovery and platform diversification, but faces risks from geopolitical disruptions, fuel costs, and rising debt levels. Current valuation metrics (P/E 267, P/S 6.07) suggest premium pricing requiring sustained execution. Institutional sentiment remains positive despite recent selling by Boston Common Asset Management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About MakeMyTrip Ltd
MakeMyTrip Ltd. is a leading online travel company in India, providing a comprehensive range of travel services and products, including air tickets, hotels, holiday packages, rail tickets, and bus tickets. The company operates its primary websites and mobile apps under the brands MakeMyTrip, Goibibo, and RedBus. MMYT serves as a key intermediary in India's fragmented travel market, leveraging its platform to offer convenience and competitive pricing to consumers and businesses.
Read more on MMYT →
